A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline

Phathom Pharmaceuticals (PHAT) recently reported first quarter results showing a net loss of US$30.37 million, alongside reaffirmed 2026 guidance that includes an operating profitability target beginning in the third quarter.

See our latest analysis for Phathom Pharmaceuticals.

The stock’s recent 12.62% 1 month share price return, alongside a 7.56% 7 day gain, contrasts with a 19.35% year to date share price decline. At the same time, the 1 year total shareholder return above 400% highlights how earlier moves still dominate the longer term picture.

If Phathom’s earnings update has you looking at other opportunities in healthcare, this can be a useful moment to scout 33 healthcare AI stocks

With Phathom trading at US$12.67, sitting on a very large 1 year total return and a price that is well below the average analyst target, you have to ask: is there still value here, or is the stock already pricing in future growth?

Most Popular Narrative: 46.5% Undervalued

With Phathom shares at $12.67 against a narrative fair value of $23.70, the current pricing sits well below what the prevailing storyline assumes.

VOQUEZNA’s exclusivity extended to at least 2033 reduces expected generic risk, supporting sustained high-margin revenue and earnings scalability over the medium and long term. The upcoming launch of the EoE Phase II trial and opportunity for additional indications (including potential pediatric exclusivity extension) positions Phathom to grow its addressable market and drive future top-line expansion.

Read the complete narrative.

Curious what kind of revenue curve and margin reset are baked into that view? The narrative leans on aggressive expansion and a punchy future profit multiple.

Result: Fair Value of $23.70 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, that upbeat story could be knocked off course if VOQUEZNA faces clinical or regulatory setbacks, or if U.S. reimbursement and formulary access remain tougher than expected.

Find out about the key risks to this Phathom Pharmaceuticals narrative.

Next Steps

With both risks and rewards in play, it is worth seeing the full picture for yourself sooner rather than later. You can start with 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop with just one stock today, you might miss out on opportunities that better fit your goals, risk comfort, and time horizon.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com